- The FDA authorized two additional COVID-19 at-home tests in an effort to continue increasing the availability of at-home tests amid shortages. The agency granted Laboratory Corporation of America an Emergency Use Authorizations for fits combined home collection kit for molecular testing for COVID-19 and influenza A/B. The kit will become available in early October and can be ordered by an individual’s physician. The FDA also authorized ACON Laboratories’ rapid, at-home COVID-19 test. (Press release here; Articles here and here)
- AstraZeneca PLC asked federal regulators for an Emergency Use Authorization of its COVID-19 antibody cocktail. The treatment was 77 percent effective at preventing symptomatic illness in a clinical trial and could bolster protection for people who couldn’t get vaccinated or for whom the shots were less effective. (Articles here, here, here, and here)
October 5, 2021
Life Sciences